OTCMKTS:ABLYF - Ablynx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$50.63 -2.67 (-5.01 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$50.63
Today's Range$50.63 - $50.63
52-Week Range$12.50 - $55.04
Volume175 shs
Average Volume455 shs
Market Capitalization$4.01 billion
P/E Ratio-25.70
Dividend YieldN/A
Beta8.25

About Ablynx (OTCMKTS:ABLYF)

Ablynx logoAblynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Receive ABLYF News and Ratings via Email

Sign-up to receive the latest news and ratings for ABLYF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ABLYF
CUSIPN/A
Phone329-262-0000

Debt

Debt-to-Equity Ratio0.86
Current Ratio7.07
Quick Ratio7.07

Price-To-Earnings

Trailing P/E Ratio-25.70
Forward P/E Ratio-58.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$62.73 million
Price / Sales60.74
Cash FlowN/A
Price / CashN/A
Book Value$2.71 per share
Price / Book18.68

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees329
Outstanding Shares75,250,000

Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions

What is Ablynx's stock symbol?

Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."

What price target have analysts set for ABLYF?

1 equities research analysts have issued 12 month target prices for Ablynx's shares. Their predictions range from $26.00 to $26.00. On average, they expect Ablynx's stock price to reach $26.00 in the next twelve months. View Analyst Ratings for Ablynx.

Who are some of Ablynx's key competitors?

Who are Ablynx's key executives?

Ablynx's management team includes the folowing people:
  • Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
  • Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
  • Mr. Piet Houwen, Chief Operations Officer
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer
  • Lies Vanneste, Director of Investor Relations

Has Ablynx been receiving favorable news coverage?

Media coverage about ABLYF stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ablynx earned a daily sentiment score of 0.08 on Accern's scale. They also gave media headlines about the company an impact score of 46.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Ablynx?

Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ablynx's stock price today?

One share of ABLYF stock can currently be purchased for approximately $50.63.

How big of a company is Ablynx?

Ablynx has a market capitalization of $4.01 billion and generates $62.73 million in revenue each year. The company earns $-122,670,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Ablynx employs 329 workers across the globe.

How can I contact Ablynx?

Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000.


MarketBeat Community Rating for Ablynx (ABLYF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLYF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ablynx (OTCMKTS:ABLYF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Ablynx in the last 12 months. Their average twelve-month price target is $26.00, suggesting that the stock has a possible downside of 48.65%. The high price target for ABLYF is $26.00 and the low price target for ABLYF is $26.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.00$26.00$26.00$26.00
Price Target Upside: 48.65% downside25.60% upside25.60% upside25.60% upside

Ablynx (OTCMKTS:ABLYF) Consensus Price Target History

Price Target History for Ablynx (OTCMKTS:ABLYF)

Ablynx (OTCMKTS:ABLYF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/10/2017Bank of AmericaInitiated CoverageBuy$26.00View Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dividends

Ablynx (OTCMKTS:ABLYF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ablynx (OTCMKTS ABLYF) Insider Trading and Institutional Ownership History

Insider Trading History for Ablynx (OTCMKTS:ABLYF)

Ablynx (OTCMKTS ABLYF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ablynx (OTCMKTS ABLYF) News Headlines

Source:
DateHeadline
Ablynx completes enrollment in mid-stage study of ALX-0171 in RSVAblynx completes enrollment in mid-stage study of ALX-0171 in RSV
seekingalpha.com - April 30 at 10:41 AM
ABLYNX (ABLYF) Raised to Hold at Zacks Investment ResearchABLYNX (ABLYF) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 2 at 4:46 PM
ABLYNX (ABLYF) Lifted to "Hold" at Zacks Investment ResearchABLYNX (ABLYF) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:38 PM
PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018
feeds.benzinga.com - March 29 at 1:28 AM
Here’s What’s Moving Protagonist And Ablynx Right NowHere’s What’s Moving Protagonist And Ablynx Right Now
finance.yahoo.com - March 26 at 3:39 PM
Ablynxs vobarilizumab flunks mid-stage lupus studyAblynx's vobarilizumab flunks mid-stage lupus study
seekingalpha.com - March 26 at 10:59 AM
ABLYNX (ABLYF) Upgraded to Hold by ValuEngineABLYNX (ABLYF) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
ABLYNX ANNOUNCES WARRANT EXERCISEABLYNX ANNOUNCES WARRANT EXERCISE
feeds.benzinga.com - March 15 at 2:49 AM
Mid-stage study underway in Japan for Ablynx ALX-0171 in RSVMid-stage study underway in Japan for Ablynx ALX-0171 in RSV
seekingalpha.com - March 2 at 10:23 AM
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed UpdateYour Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
seekingalpha.com - February 15 at 3:47 PM
ABLYNX (ABLYF) Set to Announce Earnings on ThursdayABLYNX (ABLYF) Set to Announce Earnings on Thursday
www.americanbankingnews.com - February 15 at 2:56 AM
Born From Frozen Camel Blood, Ablynx Is $4.8 Billion PrizeBorn From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize
finance.yahoo.com - January 29 at 8:31 AM
Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for AblynxSanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx
finance.yahoo.com - January 29 at 8:31 AM
[$$] Sanofi to Buy Ablynx for €3.9 Billion[$$] Sanofi to Buy Ablynx for €3.9 Billion
finance.yahoo.com - January 29 at 8:31 AM
5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know
finance.yahoo.com - January 29 at 8:31 AM
ABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICERABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICER
feeds.benzinga.com - January 24 at 3:39 AM
Jefferies Group Brokers Increase Earnings Estimates for ABLYNX (ABLYF)Jefferies Group Brokers Increase Earnings Estimates for ABLYNX (ABLYF)
www.americanbankingnews.com - January 19 at 8:16 AM
Jefferies Group Analysts Raise Earnings Estimates for ABLYNX (ABLYF)Jefferies Group Analysts Raise Earnings Estimates for ABLYNX (ABLYF)
www.americanbankingnews.com - January 18 at 11:30 PM
Zacks Investment Research Lowers ABLYNX (ABLYF) to HoldZacks Investment Research Lowers ABLYNX (ABLYF) to Hold
www.americanbankingnews.com - January 18 at 4:46 PM
ABLYNX (ABLYF) Raised to "Buy" at Zacks Investment ResearchABLYNX (ABLYF) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 17 at 4:42 PM
Zacks Investment Research Downgrades ABLYNX (ABLYF) to HoldZacks Investment Research Downgrades ABLYNX (ABLYF) to Hold
www.americanbankingnews.com - January 12 at 4:28 PM
ABLYNX (ABLYF) Upgraded by Zacks Investment Research to "Buy"ABLYNX (ABLYF) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 8 at 10:48 PM
Novo Nordisk Makes Unsolicited Bid for AblynxNovo Nordisk Makes Unsolicited Bid for Ablynx
finance.yahoo.com - January 8 at 11:54 AM
ABLYNX (ABLYF) Downgraded by Zacks Investment Research to "Hold"ABLYNX (ABLYF) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 5 at 4:52 PM
ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
feeds.benzinga.com - January 4 at 3:01 AM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : January 2, 2018Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : January 2, 2018
finance.yahoo.com - January 2 at 8:50 AM
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATIONABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
feeds.benzinga.com - December 7 at 2:25 AM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : December 5, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : December 5, 2017
finance.yahoo.com - December 5 at 9:10 AM
Ablynx Nv (ABLYF) Upgraded at Zacks Investment ResearchAblynx Nv (ABLYF) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 22 at 10:48 PM
Ablynx Nv Expected to Post FY2017 Earnings of ($1.29) Per Share (ABLYF)Ablynx Nv Expected to Post FY2017 Earnings of ($1.29) Per Share (ABLYF)
www.americanbankingnews.com - November 22 at 6:46 AM
Ablynx NV – Value Analysis (US OTC:ABLYF) : October 27, 2017Ablynx NV – Value Analysis (US OTC:ABLYF) : October 27, 2017
finance.yahoo.com - October 27 at 5:32 PM
Ablynx NV breached its 50 day moving average in a Bearish Manner : ABLYF-US : October 26, 2017Ablynx NV breached its 50 day moving average in a Bearish Manner : ABLYF-US : October 26, 2017
finance.yahoo.com - October 26 at 11:39 AM
ETFs with exposure to Ablynx NV : October 26, 2017ETFs with exposure to Ablynx NV : October 26, 2017
finance.yahoo.com - October 26 at 11:39 AM
3 Things In Biotech You Should Learn Today: October 4, 20173 Things In Biotech You Should Learn Today: October 4, 2017
seekingalpha.com - October 5 at 3:13 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : September 28, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : September 28, 2017
finance.yahoo.com - October 2 at 3:13 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : September 15, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : September 15, 2017
finance.yahoo.com - September 15 at 3:27 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : August 28, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : August 28, 2017
finance.yahoo.com - August 28 at 3:28 PM
Ablynx NV :ABLYF-US: Earnings Analysis: For the six months ended June 30, 2017 : August 28, 2017Ablynx NV :ABLYF-US: Earnings Analysis: For the six months ended June 30, 2017 : August 28, 2017
finance.yahoo.com - August 28 at 3:27 PM
Ablynxs (ABLYF) CEO Edwin Moses on Q2 2017 Results - Earnings Call TranscriptAblynx's (ABLYF) CEO Edwin Moses on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 26 at 3:17 PM
Ablynx NV – Value Analysis (US OTC:ABLYF) : August 25, 2017Ablynx NV – Value Analysis (US OTC:ABLYF) : August 25, 2017
finance.yahoo.com - August 25 at 10:02 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : November 11, 2015Ablynx NV breached its 50 day moving average in a Bullish Manner : November 11, 2015
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV breached its 50 day moving average in a Bearish Manner : January 18, 2016Ablynx NV breached its 50 day moving average in a Bearish Manner : January 18, 2016
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV Earnings Analysis: 2015 By the NumbersAblynx NV Earnings Analysis: 2015 By the Numbers
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV breached its 50 day moving average in a Bearish Manner : ABLYF-US : June 13, 2016Ablynx NV breached its 50 day moving average in a Bearish Manner : ABLYF-US : June 13, 2016
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV :ABLYF-US: Earnings Analysis: Q1, 2016 By the Numbers : July 12, 2016Ablynx NV :ABLYF-US: Earnings Analysis: Q1, 2016 By the Numbers : July 12, 2016
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : December 12, 2016Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : December 12, 2016
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV – Value Analysis (US OTC:ABLYF) : December 13, 2016Ablynx NV – Value Analysis (US OTC:ABLYF) : December 13, 2016
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV :ABLYF-US: Earnings Analysis: For the six months ended December 31, 2016 : April 7, 2017Ablynx NV :ABLYF-US: Earnings Analysis: For the six months ended December 31, 2016 : April 7, 2017
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : May 8, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : May 8, 2017
finance.yahoo.com - August 17 at 12:38 PM
Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : August 17, 2017Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : August 17, 2017
finance.yahoo.com - August 17 at 12:38 PM

SEC Filings

Ablynx (OTCMKTS:ABLYF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Ablynx (OTCMKTS ABLYF) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.